title: Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption.
authors.forename: A
authors.initials: A
authors.lastname: Laroni
authors.forename: D
authors.initials: D
authors.lastname: Brogi
authors.forename: V
authors.initials: V
authors.lastname: Milesi
authors.forename: L
authors.initials: L
authors.lastname: Abate
authors.forename: A
authors.initials: A
authors.lastname: Uccelli
authors.forename: Gl
authors.initials: G
authors.lastname: Mancardi
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D057915:Drug Substitution; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D000069442:Natalizumab; D011409:Propylene Glycols / Q000008:administration & dosage*; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; D000069442:Natalizumab; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine